Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Orforglipron 6mg / 90caps
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
Orforglipron is a synthetic, non-peptidic GLP-1 receptor agonist studied in controlled research environments for its role in modulating glucagon-like peptide-1 signalling pathways. Research focuses on its activity in cAMP-dependent pathways, receptor activation dynamics, and peptide-regulated energy balance mechanisms. Unlike traditional GLP-1 analogues, Orforglipron demonstrates oral bioactivity and high receptor selectivity, making it suitable for experimental models evaluating small molecule agonists in metabolic signalling systems.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
| Chemical Formula | C48H48F2N10O5 |
|---|---|
| Synonyms | LY3502970, OWL833, Foundayo (trade name) |
| Molar Mass | 883.0 g/mol |
| CAS Number | 2212020-52-3 |
| PubChem CID | 137319706 |
| Total Compound Content | 540 mg (6 mg per capsule) |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
How does Orforglipron's binding mechanism differ from peptide GLP-1R agonists?
Peptide GLP-1R agonists interact primarily with the receptor's extracellular peptide-binding domain, whereas Orforglipron binds within the transmembrane region of GLP-1R through a distinct small-molecule binding site. This alternative binding mode stabilizes an active receptor conformation through a mechanism different from endogenous peptide ligands. As a result, Orforglipron is a valuable research tool for investigating allosteric receptor activation, receptor conformational dynamics, and the differences between peptide-mediated and small-molecule-mediated GLP-1R signalling.
What advantages does Orforglipron provide for GLP-1R pharmacology research?
As an orally active small-molecule agonist, Orforglipron enables investigation of GLP-1R activation without the structural constraints associated with peptide ligands. This makes it useful for studies examining receptor binding-site architecture, signal-transduction mechanisms, receptor trafficking, ligand-specific signalling profiles, and the development of non-peptide class B GPCR agonists. Its distinct binding mode also allows direct comparison of orthosteric versus non-orthosteric receptor activation mechanisms.
Why is Orforglipron important for studying GLP-1 receptor signalling?
Orforglipron provides a unique platform for exploring how different ligand classes activate the same receptor. Comparative studies can evaluate receptor activation kinetics, cAMP signalling, receptor internalisation, signalling bias, and conformational changes induced by small-molecule versus peptide agonists. These investigations contribute to a broader understanding of GLP-1R pharmacology and class B GPCR activation mechanisms.
-
-
-
-
-
SALE
